Immunological features predict treatment response for advanced solid tumors

Jeffrey Lee named chief medical executive at MD Anderson

Jeffrey E. Lee was appointed chief medical executive at The University of Texas MD Anderson Cancer Center, effective April 1.

March 28, 2025

Vol.51 No.12

In Brief

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

Physician-scientist Theodore Scott Nowicki, an assistant professor-in-residence of pediatric hematology/oncology and microbiology, immunology, and molecular genetics at the David Geffen School of Medicine at UCLA, has been awarded a $4.5 million R37 MERIT Award to help improve the effectiveness of cellular therapies for solid tumors.

March 21, 2025

Vol.51 No.11

In Brief

MD Anderson and Texas Children’s Hospital announce joint venture focused on childhood cancer

The University of Texas MD Anderson Cancer Center and Texas Children’s Hospital have announced a collaboration focused on pediatric cancer care.

March 07, 2025

Vol.51 No.09

In Brief

MD Anderson receives $9M from F. W. Bert and Mae Dean Wheeler Foundation

The University of Texas MD Anderson Cancer Center received a $9 million gift from the F. W. Bert and Mae Dean Wheeler Foundation to establish the F. W. Bert and Mae Dean Wheeler Nurse Leadership Academy.

March 07, 2025

Vol.51 No.09

Clinical Roundup

Researchers develop antibody-toxin conjugate to boost immune response against cancer

Researchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate designed to stimulate immune-mediated eradication of tumors.

February 28, 2025

Vol.51 No.08

Clinical Roundup

New biomarker can predict cancer aggressiveness, study finds

Researchers from Fred Hutch Cancer Center and the University of Texas MD Anderson Cancer Center have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers using a new technology and computational method.

February 21, 2025

Vol.51 No.07

Immunological features predict treatment response for advanced solid tumors

YOU MAY BE INTERESTED IN

Jeffrey Lee named chief medical executive at MD Anderson

UCLA’s Theodore Scott Nowicki awarded $4.5M to advance cellular immunotherapies for solid tumors

MD Anderson and Texas Children’s Hospital announce joint venture focused on childhood cancer

MD Anderson receives $9M from F. W. Bert and Mae Dean Wheeler Foundation

Researchers develop antibody-toxin conjugate to boost immune response against cancer

New biomarker can predict cancer aggressiveness, study finds

Renew today!

Subscriber content

Never miss an issue!

Login